Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Final draft guidance

Final appraisal document (PDF 262 KB)

Committee papers (PDF 4.2 MB)

Public committee slides (PDF 1004 KB)

Final stakeholder list (PDF 167 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 414 KB)

Final scope (PDF 195 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Draft scope pre referral (PDF 213 KB)

Draft matrix pre referral (PDF 167 KB)